<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005184</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#161306</org_study_id>
    <nct_id>NCT03005184</nct_id>
  </id_info>
  <brief_title>Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2</brief_title>
  <official_title>Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that endogenous bradykinin contributes to effects of a
      combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with heart failure (HF) with reduced ejection fraction who qualify for the study
      will undergo a three-week run-in period in which any prior angiotensin-converting enzyme
      (ACE) inhibitor or angiotensin receptor blocker they were taking will be discontinued and
      they will be given valsartan 80 mg bid in a single-blind fashion. After the run-in, subjects
      will undergo four study periods in random order. During two study periods they will receive
      enalapril 10 mg bid and during two they will receive sacubitril/valsartan (LCZ696) 200 mg bid
      for seven days. On the seventh day or each period, subjects will complete a study day in
      which they are randomized to receive either the bradykinin B2 receptor blocker icatibant or
      placebo intravenously. Each study period will be separated by a three-week washout during
      which subjects receive valsartan 80 mg bid.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study is being redesigned and submitted as a new study.
  </why_stopped>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in systolic blood pressure</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in plasma cGMP</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal plasma flow</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in diastolic blood pressure</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fractional excretion of sodium</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine albumin-to-creatinine ratio</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain natriuretic peptide (BNP) to N-terminal pro-BNP ratio</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasminogen activator inhibitor-1</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tissue plasminogen activator</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aldosterone</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine cGMP</measure>
    <time_frame>7-hour period after 7-day intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure NYHA Class I</condition>
  <condition>Heart Failure NYHA Class II</condition>
  <condition>Heart Failure NYHA Class III</condition>
  <arm_group>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80 mg bid</intervention_name>
    <description>oral medication during run-in and washout period</description>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril 10 mg bid</intervention_name>
    <description>oral medication</description>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan 200 mg bid</intervention_name>
    <description>oral medication</description>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icatibant</intervention_name>
    <description>intravenous medication</description>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous medication</description>
    <arm_group_label>S/V+Pla, S/V+I, Enal+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+I, S/V+I, Enal+Pla</arm_group_label>
    <arm_group_label>S/V+Pla, Enal+Pla, Enal+I, S/V+I</arm_group_label>
    <arm_group_label>S/V+I, S/V+Pla, Enal+I, Enal+P</arm_group_label>
    <arm_group_label>S/V+I, Enal+Pla, S/V+Pla, Enal+I</arm_group_label>
    <arm_group_label>S/V+I, Enal+I, Enal+Pla, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+Pla, S/V+I, Enal+I</arm_group_label>
    <arm_group_label>Enal+Pla, S/V+I, Enal+I, S/V+Pla</arm_group_label>
    <arm_group_label>Enal+Pla, Enal+I, S/V+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+Pla, Enal+Pla, S/V+I</arm_group_label>
    <arm_group_label>Enal+I, S/V+I, S/V+Pla, Enal+Pla</arm_group_label>
    <arm_group_label>Enal+I, Enal+Pla, S/V+I, S/V+Pla</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stable patients with a reduced EF

               1. EF less than or equal to 40% (confirmed by echocardiogram within the last six
                  months), and

               2. history of symptoms of New York Heart Association class I, II or III HF

               3. stable clinical symptoms including no hospitalizations for the last six months

               4. treatment with a stable dose of an ACEi or ARB and with a beta blocker (unless
                  contraindicated or not tolerated) for at least four weeks

               5. treatment with a stable dose of an MR antagonist for at least four weeks unless
                  not possible due to renal function or serum potassium.

          2. For female subjects, the following conditions must be met:

               1. postmenopausal status for at least one year, or

               2. status post-surgical sterilization

        Exclusion Criteria:

          1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar
             chemical classes, ACEi, ARBs, or NEPi, as well as known or suspected contraindications
             to the study drugs

          2. History of angioedema

          3. History of pancreatitis or known pancreatic lesions

          4. History of decompensated HF within the last six months (exacerbation of chronic HF
             manifested by signs and symptoms that required intravenous therapy or hospitalization)

          5. History of heart transplant or on a transplant list or with left ventricular
             assistance device

          6. Symptomatic hypotension and/or a SBP&lt;100 mmHg at screening or &lt;90 mmHg during the
             study

          7. Serum potassium &gt;5.2 mmol/L at screening or &gt;5.4 mmol/L during the study

          8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery,
             percutaneous coronary intervention, or carotid angioplasty within six months prior to
             screening

          9. Coronary or carotid artery disease likely to require surgical or percutaneous
             intervention within six months of screening

         10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or
             transient ischemic attack within six months

         11. History of ventricular arrhythmia with syncopal episodes

         12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a
             pacemaker

         13. Presence of hemodynamically significant mitral and/or aortic valve disease, except
             mitral regurgitation secondary to LV dilatation

         14. Presence of other hemodynamically significant obstructive lesions of the left
             ventricular outflow tract, including aortic and subaortic stenosis

         15. Type 1 diabetes

         16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c &gt;9%

         17. Hematocrit &lt;35%

         18. Impaired renal function (eGFR of &lt;30mL/min/1.73 m2) as determined by the four-variable
             Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is
             expressed in mg/dL and age in years:

             eGFR (mL/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if
             female)

         19. Use of hormone-replacement therapy

         20. Breast feeding and pregnancy

         21. History or presence of immunological or hematological disorders

         22. History of malignancy other than non-melanoma skin cancer

         23. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week

         24. Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

         25. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino
             transaminase (ALT) &gt;3.0 x upper limit of normal range]

         26. Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult, such as arthritis treated with non-steroidal
             anti-inflammatory drugs

         27. Treatment with chronic systemic glucocorticoid therapy within the last year

         28. Treatment with lithium salts

         29. History of alcohol or drug abuse

         30. Treatment with any investigational drug in the one month preceding the study

         31. Mental conditions rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

         32. Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Hugh J. Morgan Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
    <mesh_term>Icatibant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

